pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Apr 30·2 min read
save

STAT+: DOJ, Elevance spar over access to top exec in Medicare Advantage fraud case

Elevance said a top exec would depart, days after the Justice Department asked to depose him.

Apr 30, 2026·read at STAT ↗

STAT PlusInsurance DOJ, Elevance spar over access to top exec in Medicare Advantage fraud case Elevance ‘refuses’ to make Peter Haytaian available for deposition, Justice Department says Manage alerts for this article Email this article Share this article By Bob HermanApril 30, 2026 Bob Herman is the author of Health Care Inc., an award-winning weekly newsletter about the business of health and medicine. Bob Herman[email protected]Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also the author of the Health Care Inc.

newsletter. You can reach Bob on Signal at bobjherman.09. One of the biggest Medicare Advantage fraud cases has hit a snag, with government officials saying they don’t have access to a key witness.

Elevance Health is blocking the deposition of Peter Haytaian, an outgoing executive who previously oversaw the health insurer’s Medicare Advantage plans, Department of Justice attorneys said this week in a letter to a judge. The letter also revealed how Elevance announced Haytaian’s departure right after DOJ first asked to depose him.Advertisement The dispute underscores the high stakes of the lawsuit, which the DOJ initiated in 2020. It also adds to the wide-ranging scrutiny facing Elevance’s private Medicare plans for seniors, which generated more than $40 billion of revenue last year.

STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+. Already have an account?

Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.

Subscribe Log In legal, medicare advantage, Policy, STAT+ Submit a correction requestReprints Bob Herman Business of Health Care Reporter Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also the author of the Health Care Inc. newsletter.

You can reach Bob on Signal at bobjherman.09. Newsletter Unpacking the business — and secretive inner workings — of the U.S. health care industry Recommended Pharmalot April 30, 2026 STAT Plus: FDA wants to exclude weight loss drugs from a compounding list The Readout April 30, 2026 STAT Plus: Five-way obesity drug is super effective — in mice Advertisement Breaking News April 30, 2026 STAT Plus: Cigna will exit ACA individual markets next year, adding to tumult for patients The Readout April 29, 2026 STAT Plus: A patent win for Pfizer and BridgeBio Biotech April 28, 2026 STAT Plus: FDA launches effort to speed up clinical trials, using AI Subscriber Picks

source

Reporting by STAT.

read at STAT ↗
519 words · retrieved Apr 30
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
PFIZER
drugs
Obesity
topics
Obesity2

related stories

  • Jun 8STAT+: Novo underwhelmed by drug it once fought Pfizer forSTAT
  • Jun 8STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and moreSTAT
  • Jun 8STAT+: J&J spends $1 billion to enter KRAS race for cancer treatmentsSTAT
  • Jun 8Major readouts from the annual diabetes conferenceSTAT
  • Jun 8STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rateSTAT